N-Glycomic profiling reveals dysregulated glycans related to oral cancer using MALDI-MS

• Published in: Analytical and bioanalytical chemistry Vol. 414; no. 5; pp. 1881 - 1890
• Main Authors: Wu, Yike, Liu, Yuanyuan, Shang, Zhengjun, Liu, Xin, Xu, Yong, Liu, Wenlan
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022; Springer; Springer Nature B.V
• Subjects: Analysis; Analytical Chemistry; Biochemistry; Biomarkers; Cancer; Characterization and Evaluation of Materials; Chemistry; Chemistry and Materials Science; Data analysis; Diagnosis; Food Science; Glycan; Glycomics; Glycosylation; Humans; Identification and classification; Laboratory Medicine; Malignancy; Mass spectrometry; Methods; Monitoring/Environmental Analysis; Mouth cancer; Mouth Neoplasms - metabolism; Multivariate analysis; Oral cancer; Polysaccharides; Polysaccharides - metabolism; Properties; Research Paper; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods; Statistical analysis; Structure; China; Biomarkers; MALDI-MS; N-Glycans; Oral cancer; Microvesicle
• ISSN: 1618-2642; 1618-2650
• DOI: 10.1007/s00216-021-03822-6

Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer. In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC. Various statistical analyses were used to determine differential N-glycome profiles. There were 8 glycan structures significantly increased ( p  < 0.05) in all OC-derived  microvesicles (MVs). Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC. Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures ( p  < 0.05). Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.